{
    "organizations": [],
    "uuid": "821db96be9c52d5f95641cec7909dbe73f491893",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-janssen-collaborates-with-bristol/brief-janssen-collaborates-with-bristol-myers-squibb-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1RF003",
    "ord_in_thread": 0,
    "title": "Janssen Collaborates With Bristol-Myers Squibb To Develop & Commercialize Factor XIa Inhibitors",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - Janssen Pharmaceutical Companies:\n* JANSSEN ANNOUNCES WORLDWIDE DEVELOPMENT & COMMERCIALIZATION COLLABORATION WITH BRISTOL-MYERS TO ADVANCE THERAPY FOR CARDIOVASCULAR DISEASES\n* THE JANSSEN PHARMACEUTICAL COMPANIES - ENTERED WORLDWIDE COLLABORATION WITH BRISTOL-MYERS TO DEVELOP, COMMERCIALIZE FACTOR XIA INHIBITORS\n* JANSSEN - UNDER AGREEMENT, CO, BRISTOL-MYERS SQUIBB TO ADVANCE BMS-986177 INTO PHASE 2 CLINICAL TRIALS\n* JANSSEN - COS TO SHARE DEVELOPMENT COSTS, COMMERCIAL PROFITS AND LOSSES; ADDITIONAL TERMS OF AGREEMENT NOT DISCLOSED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-17T05:08:00.000+03:00",
    "crawled": "2018-04-17T00:20:31.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "janssen",
        "pharmaceutical",
        "company",
        "janssen",
        "announces",
        "worldwide",
        "development",
        "commercialization",
        "collaboration",
        "advance",
        "therapy",
        "cardiovascular",
        "disease",
        "janssen",
        "pharmaceutical",
        "company",
        "entered",
        "worldwide",
        "collaboration",
        "develop",
        "commercialize",
        "factor",
        "xia",
        "inhibitor",
        "janssen",
        "agreement",
        "co",
        "squibb",
        "advance",
        "phase",
        "clinical",
        "trial",
        "janssen",
        "co",
        "share",
        "development",
        "cost",
        "commercial",
        "profit",
        "loss",
        "additional",
        "term",
        "agreement",
        "disclosed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}